骨髓纤维化脾切除术后生存的危险因素及预后模型
该研究纳入120例连续接受脾切除术的骨髓纤维化患者(中位年龄66岁),分析脾切除术后生存的危险因素并构建预后模型。中位随访1.3年,中位脾切除术后生存1.5年;年龄>65岁、输血需求、白细胞计数>25×10(9)/L和循环原始细胞≥5%为不良预后因素,据此构建的风险评分将患者分为高危(3-4个危险因素)、中危(2个)和低危(0-1个),对应中位生存分别为0.3、1.3和2.9年。
要点
- 脾切除术后中位生存1.5年,95例(79%)死亡,30例(25%)发生白血病转化。
- 年龄>65岁、输血需求、白细胞>25×10(9)/L、循环原始细胞≥5%为不良预后因素。
- 风险评分高危(3-4个因素)中位生存0.3年(HR 5.9,95%CI 3.2-11.0),低危(0-1个)2.9年。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Palliative treatment in myelofibrosis (MF) includes transfusion support, JAK2 inhibitors, involved field radiotherapy and splenectomy. To assist in selecting patients who are likely to benefit from splenectomy, we looked into risk factors for postsplenectomy survival, in 120 consecutive cases (median age 66 years); at the time of splenectomy, 61% displayed red cell transfusion need, 49% platelet count <100 × 10(9)/L, 25% leukocyte count >25 × 10(9)/L, 60% constitutional symptoms and 13% circulating blasts ≥5%; dynamic international prognostic scoring system risk categories were 21% high, 55% intermediate-2, 21% intermediate-1 and 3% low. Among informative cases, karyotype was abnormal in 60% and driver mutational status was JAK2 75%, CALR 15%, MPL 4% and triple-negative 6%. At median follow-up of 1.3 years, from time of splenectomy, 95 (79%) deaths and 30 (25%) leukemic transformations were recorded. Median postsplenectomy survival was 1.5 years; in multivariable analysis, survival was adversely affected by age >65 years, transfusion need, leukocyte count >25 × 10(9)/L and circulating blasts ≥5%; these variables were subsequently used to devise an HR-weighted scoring system with high (3-4 risk factors), intermediate (2 risk factors) and low (0-1 risk factors) risk categories; the corresponding postsplenectomy median survivals were 0.3 (HR 5.9, 95% CI 3.2-11.0), 1.3 (HR 2.9, 95% CI 1.8-4.6) and 2.9 years. Postsplenectomy survival was not affected by driver mutational status or occurrence of leukemic transformation. Leukemia-free survival was predicted by very high risk karyotype. The observations from the current study might help identify appropriate candidates for splenectomy in MF.
引用
- Tefferi A, Mudireddy M, Gangat N, et al. Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. Am J Hematol. 2017. PMID: 28782256. doi:10.1002/ajh.24881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。